Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40259-020-00429-8 http://scihub22266oqcxt.onion/10.1007/s40259-020-00429-8 32583318!7312107!32583318     free     free     free       BioDrugs 2020 ; 34 (4): 423-433 Nephropedia Template TP {{tp|p=32583318|t=2020. Beyond Antibodies: The DARPin((R)) Drug Platform |pdf=|usr=}}{{32583318}} gab.com Text Beyond Antibodies: The DARPin((R)) Drug Platform JO: BioDrugs http://www.kidney.de/pget.php?&tw=1&pmid=32583318 #FOAvip The DARPin((R)) drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows for the generation of diverse, well-behaved, multifunctional drug candidates. Recent clinical data illustrate the favorable safety profile of the first DARPin((R)) molecules tested in patients. With the positive phase III results of the most advanced DARPin((R)) drug candidate, abicipar, the DARPin((R)) drug platform is potentially about to achieve its first marketing approval. This review highlights some of the key milestones and decisions encountered when transforming the DARPin((R)) platform from an academic concept to a biotech drug pipeline engine. Twit Text FOAVip Beyond Antibodies: The DARPin((R)) Drug Platform ????BioDrugs http://www.kidney.de/pget.php?&tw=1&pmid=32583318 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32583318 #FOAvip English Wikipedia <ref>{{Cite pmid|32583318}}</ref> Beyond Antibodies: The DARPin((R)) Drug Platform #MMPMID32583318 Stumpp MT; Dawson KM; Binz HK BioDrugs 2020[Aug]; 34 (4): 423-433 PMID32583318show ga The DARPin((R)) drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows for the generation of diverse, well-behaved, multifunctional drug candidates. Recent clinical data illustrate the favorable safety profile of the first DARPin((R)) molecules tested in patients. With the positive phase III results of the most advanced DARPin((R)) drug candidate, abicipar, the DARPin((R)) drug platform is potentially about to achieve its first marketing approval. This review highlights some of the key milestones and decisions encountered when transforming the DARPin((R)) platform from an academic concept to a biotech drug pipeline engine. |*Ankyrin Repeat[MESH] |*Pharmaceutical Preparations[MESH] |Antibodies, Monoclonal/*chemistry/immunology[MESH]Beyond Antibodies: The DARPin((R)) Drug Platform (epmc).pdf DeepDyve Pubget Overpricing